//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts
Loading...
Amazing talk Mark Dawson! Clear, cool and sharp 😎
20d
Such a nice talk! Richard was on fire 😎
It's starting 🤩
Our next seminar! Link: umontpellier-fr.zoom.us/j/97110019808
Bonjour à tous, Les inscriptions pour notre formation annuelle sur les technologies émergentes pour explorer l'hétérogénéité tumorale sont ouvertes ! N'hésitez pas à vous inscrire et/ou à partager à votre réseau 😀
It's today!! 🤗
Our next seminar! Link: umontpellier-fr.zoom.us/j/97110019808
19d
20d
6mo
SUNRiSE network
8e Formation SUNRiSE : 2 & 3 mars 2026! Venez vous former aux technologies récentes pour étudier les cellules souches cancéreuses et la plasticité tumorale auprès d'experts dans le domaine! Informations ici: www.sunrise-network.fr/fr/event/7e-...
4mo
5mo
6mo
4mo
www.nature.com/articles/s41...
SUNRiSE network
4mo
SUNRiSE network
SUNRiSE network
SUNRiSE network
SUNRiSE network
SUNRiSE network
HETEROGENEITE ET PLASTICITE TUMORALE : LES NOUVELLES TECHNOLOGIES POUR EXPLORER L’ECOSYSTEME TUMORAL 8e SESSION DE FORMATION DU RESEAU SUNRiSE 2 au 3 mars 2026, On line Objectif : Cette formation se d...
www.sunrise-network.fr
8e Formation SUNRiSE : 2 & 3 mars 2026 - Sunrise
🚨 Early-bird deadline approaching! 1st of April... 🔬 Discover cutting-edge research 🤝 Connect with peers and experts 💡 Exclusive "Meet" the editor session 🏆 Awards for the best oral and poster presentations for young researchers @sunrise-network.bsky.social
SUNRiSE network
6mo
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
www.nature.com
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial - Nature Medicine
2mo
Our next seminar! Link: umontpellier-fr.zoom.us/j/97110019808
Aguirre-Ghiso Lab
SUNRiSE network